Evidence map›Paper›PMID 41286210›Full record

ReviewDiscover oncology2025

Nanomedicine and nutraceutical-based nanocarriers for specific delivery to cancer stem cells: targeted drug delivery at the STEM frontier.

Enas Daoud, Waleed K Abdulsahib, Sajida Hussein Ismael, R Roopashree, Subhashree Ray, Jayshree Nellore, Gunjan Mukherjee, Ashish Singh Chauhan, Mohigul Kholiyeva

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Enas DaoudFaculty of Pharmacy, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Waleed K AbdulsahibDepartment of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq. waleedk.abdulsahib@uoalfarahidi.edu.iq.ORCID http://orcid.org/0000-0002-8851-5783
Sajida Hussein IsmaelCollege of Pharmacy, Al-Turath University, Baghdad, Iraq.
R RoopashreeDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Subhashree RayDepartment of Biochemistry, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, Odisha, 751003, India.
Jayshree NelloreDepartment of Biotechnology, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Gunjan MukherjeeUniversity Institute of Biotechnology, Chandigarh University, Mohali, Punjab, India.
Ashish Singh ChauhanUttaranchal Institute of Pharmaceutical Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.
Mohigul KholiyevaDepartment of Medicine, Termez University of Economics and Service, Termez, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) represent a highly plastic and therapy-resistant subpopulation within tumors, driving tumor initiation, progression, metastasis, and relapse. Their ability to evade conventional treatments necessitates novel, highly specific therapeutic strategies. Nanomedicine offers a transformative approach to overcome the limitations of traditional therapies by enabling targeted and controlled drug delivery. This review explores the synergistic potential of combining advanced nanocarriers with potent nutraceuticals, emphasizing their capacity to modulate critical CSC signaling pathways and overcome inherent bioavailability challenges. The review first outlines the unique biological characteristics of CSCs that make them elusive therapeutic targets. It then delineates the principles of nanomedicine for precise drug delivery and details the anti-CSC mechanisms of various promising nutraceuticals. Furthermore, it examines innovative nanocarrier-based strategies designed for specific CSC targeting, such as curcumin-loaded solid lipid nanoparticles and resveratrol-hydrogels, presenting compelling preclinical evidence. Finally, the report addresses the significant translational challenges that must be overcome for these advanced therapies to reach clinical fruition, underscoring the transformative potential of emerging technologies, such as biomimetics, microfluidics, and artificial intelligence, in advancing targeted CSC therapies at the “STEM Frontier” of oncology.

Indexed as

Biomimetic nanoparticlesCancer stem cellsMicrofluidicsNanomedicineNutraceuticalsTargeted drug deliveryTherapy resistance

Identifiers

PMID41286210
PMCPMC12748364

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.